BioInvent International, a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, has announced that Pfizer has selected antibodies directed at a previously-selected target under the companies’ cancer immunotherapy research collaboration and licence agreement.
The agreement, into which the companies entered in December 2016, covers developing antibodies from BioInvent’s proprietary F.I.R.S.TTM drug discovery platform targeting tumour-associated myeloid cells.
The selection of these antibodies triggers a payment of $3 million from Pfizer to BioInvent, and BioInvent is eligible for further milestone payments from development of these antibodies and potential selection and development of further antibodies directed at the same target.
Martin Welschof, BioInvent’s CEO, said: “Pfizer’s selection of antibodies under our agreement is a great demonstration of the actionable leads generated by our drug discovery technology platform. We are very pleased with how our partnership is progressing and look forward to further strengthening our collaboration.
“Our F.I.R.S.TTM platform is a patient-centric approach, drawing on our high-quality n-CoDeR antibody library to produce promising drug candidates, and we believe this partnership is an important validation of this technology.”
Darcy Jimenez
This is a syndicated feed from Pharmafile
